Abstract: Objective To explore the prevalence of metabolic syndrome（MetS） and non-alcoholic fatty liver diseases（NAFLD） in patients with lung cancer. Methods We retrospectively analyzed the clinical data of patients with lung cancer in Shanghai Pulmonary Hospital in 2013. The results of biochemical indexes were obtained by Hitachi 700 full-automatic biochemical analyzers，and the diagnosis of NAFLD was made by Vivid 7 color dropper ultasound instruments from GE company or SONOLINE 50 color dropper ultasound instruments from SIMENS company. Results Among 675 patients with lung cancer，391（57.9%） were male and 284 （42.1%） female with the average age of （59.7±9.71） yr old；165 （24.4%） cases had MetS，and the prevalences of MetS in patients with adenocarcinoma，squamous cell carcinoma，small cell lung cancer and other types of lung cancer was 25.7% （117/456），22.3% （33/148），21.1%（15/71）and 21.1% （15/71），and the differences among them were not significantly（x2=1.244，P=0.743）；the proportion of elevated serum triglycerides in pulmonary adenocarcinoma was higher than in with squamous cell lung carcinoma（25.4% vs. 17.4%，P=0.047）；There was no significant difference as respect to the prevalence of MetS and/or NAFLD between 456 patients with adenocarcinoma and 219 with non-adenocarcinoma（P＞0.05）. Conclusion Hypertriglyceridemia and NAFLD might be the risk factors for the occurrence of lung adenocarcinoma.

Key words: Lung cancer, Metabolic syndrome, Non-alcoholic fatty liver diseases, Hypertriglyceridemia